(Q41436212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Machelle Wilchesky

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Rob J van Marum

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Toine Egberts

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

Mieke Berkers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Pierre-Hugues Carmichael

5

object named as

Pierre-Hugues Carmichael

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Marie Mouls

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Patrick Souverein

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marie-Laure Laroche

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

31 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1197-1206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26324356%20AND%20SRC:MED&resulttype=core&format=json

2012 Alzheimer's disease facts and figures

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

The worldwide societal costs of dementia: Estimates for 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Prevalence of cholinesterase inhibitors in subjects with dementia in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Predicting and preventing adverse drug reactions in the very old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Adverse effects associated with the use of donepezil in general practice in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Quantitative signal detection using spontaneous ADR reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274

Under-reporting of adverse drug reactions : a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015602274